Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7638598 | 0.86 | CYP2C19 (0.47) | CYP1A2CYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL17316190 | 0.86 | CYP2C19 (0.47) | CYP1A2CYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL16910204 | 0.86 | CYP2C19 (0.47) | CYP1A2CYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL12208397 | 0.82 | CYP1A2 (0.33) | CYP1A2CYP2C19LMNATSHRSCN9A | |
| SCHEMBL8128760 | 0.75 | KMT2A (0.38) | CYP1A2CYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL14012881 | 0.74 | SLC6A2 (0.43) | CYP1A2CYP2C19LMNATSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3716032 | 0.74 | CYP2C19 (0.37) | CYP1A2CYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL15105805 | 0.74 | — | — | |
| SCHEMBL15125268 | 0.74 | — | — | |
| SCHEMBL16449069 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106058-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1109909-B1 | GRF ANALOGS WITH INCREASED BIOLOGICAL POTENCY | THERATECHNOLOGIES INC (CA) | 2005-11-30 | — | — | EP | disclosed |
| US-20040171534-A1 | GRF analogs with increased biological potency | THERATECHNOLOGIES, INC. (CA) | 2004-09-02 | — | — | US | disclosed |
| US-6458764-B1 | CHIMERIC FATTY BODY-GRF ANALOGS WITH INCREASED BIOLOGICAL POTENCY, THEIR APPLICATION AS ANABOLIC AGENTS AND IN THE DIAGNOSIS AND TREATMENT OF GROWTH HORMONE DEFICIENCIES. THE CHIMERIC FATTY BODY-GRF ANALOGS INCLUDE AN HYDROPHOBIC MOIETY | THERATECHNOLOGIES INC. (CA) | 2002-10-01 | — | — | US | disclosed |
| EP-1109909-A2 | GRF ANALOGS WITH INCREASED BIOLOGICAL POTENCY | THERATECHNOLOGIES INC. (CA) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000014236-A2 | GRF ANALOGS WITH INCREASED BIOLOGICAL POTENCY | THERATECHNOLOGIES INC. (CA) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | CYP1A2 1349/4885CYP2C19 1191/4885LMNA 2814/4885 |
| US-20040171534-A1 | GRF analogs with increased biological potency | GHRHR, GHITM, GHSR | CYP1A2 3179/4885CYP2C19 3724/4885LMNA 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.